PL1654353T3 - Nowotworowe linie komórkowe NM-F9 (DSM ACC2606) i NM-D4 (DSM ACC2605) oraz ich zastosowanie - Google Patents

Nowotworowe linie komórkowe NM-F9 (DSM ACC2606) i NM-D4 (DSM ACC2605) oraz ich zastosowanie

Info

Publication number
PL1654353T3
PL1654353T3 PL04764266T PL04764266T PL1654353T3 PL 1654353 T3 PL1654353 T3 PL 1654353T3 PL 04764266 T PL04764266 T PL 04764266T PL 04764266 T PL04764266 T PL 04764266T PL 1654353 T3 PL1654353 T3 PL 1654353T3
Authority
PL
Poland
Prior art keywords
dsm
threreof
cell lines
tumour cell
acc2605
Prior art date
Application number
PL04764266T
Other languages
English (en)
Inventor
Steffen Goletz
Hans Baumeister
Marion Schlangstedt
Ute SCHÖBER
Original Assignee
Glycotope Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycotope Gmbh filed Critical Glycotope Gmbh
Publication of PL1654353T3 publication Critical patent/PL1654353T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL04764266T 2003-08-18 2004-08-18 Nowotworowe linie komórkowe NM-F9 (DSM ACC2606) i NM-D4 (DSM ACC2605) oraz ich zastosowanie PL1654353T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03018576 2003-08-18
EP04764266.5A EP1654353B1 (en) 2003-08-18 2004-08-18 Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses threreof
PCT/EP2004/009281 WO2005017130A2 (en) 2003-08-18 2004-08-18 Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses thereof

Publications (1)

Publication Number Publication Date
PL1654353T3 true PL1654353T3 (pl) 2013-11-29

Family

ID=34178385

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04764266T PL1654353T3 (pl) 2003-08-18 2004-08-18 Nowotworowe linie komórkowe NM-F9 (DSM ACC2606) i NM-D4 (DSM ACC2605) oraz ich zastosowanie

Country Status (9)

Country Link
US (2) US8017388B2 (pl)
EP (1) EP1654353B1 (pl)
CY (1) CY1114643T1 (pl)
DK (1) DK1654353T3 (pl)
ES (1) ES2425475T3 (pl)
PL (1) PL1654353T3 (pl)
PT (1) PT1654353E (pl)
SI (1) SI1654353T1 (pl)
WO (1) WO2005017130A2 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1530628T3 (da) * 2002-08-16 2011-01-10 Glycotope Gmbh Fremgangsmåde til fremstilling af temperaturinducerede tumorcellelysater til anvendelse som immunogene forbindelser
SI1654353T1 (sl) 2003-08-18 2013-09-30 Glycotope Gmbh Tumorski celični liniji NM-F9 (DSM ACC2606) in NM-D4 (DSM ACC2605), njihove uporabe
CN103627670B (zh) 2004-02-13 2016-12-21 格莱克托普有限公司 高活性糖蛋白加工条件及其有效生产方法
EP1900750A1 (en) * 2006-09-18 2008-03-19 Glycotope Gmbh Fully human high yield production system for improved antibodies
EP1911766A1 (en) * 2006-10-13 2008-04-16 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
EP3539981A1 (en) 2006-09-10 2019-09-18 Glycotope GmbH Use of human cells of myeloid leukaemia origin for expression of antibodies
PL1920781T3 (pl) 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2347769A1 (en) 2010-01-20 2011-07-27 Glycotope GmbH Cancer stem cell markers and uses thereof
US20130130317A1 (en) 2010-08-02 2013-05-23 Kyowa Hakko Kirin Co., Ltd Method for producing substance
PT2603528T (pt) 2010-08-10 2016-12-01 Glycotope Gmbh Anticorpos glicosilados em fab
WO2012091023A1 (ja) 2010-12-27 2012-07-05 協和発酵キリン株式会社 培地およびキレート剤を含む水溶液の調製方法
ES2686313T3 (es) * 2011-08-22 2018-10-17 Glycotope Gmbh Microorganismos que portan un antígeno tumoral
CN108588030B (zh) * 2018-03-30 2020-07-14 四川迈克生物新材料技术有限公司 抗人IgM单克隆抗体、其杂交瘤细胞株及应用
SG11202010496WA (en) 2018-05-18 2020-12-30 Daiichi Sankyo Co Ltd Anti-muc1 antibody-drug conjugate
EP3875595A4 (en) 2018-11-02 2022-07-13 Kyowa Kirin Co., Ltd. Liquid medium preparation method

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931275A (en) * 1985-12-02 1990-06-05 Yeda Research & Development Co., Ltd. Anti-tumor vaccines and their preparation
JP3626187B2 (ja) 1993-06-07 2005-03-02 バイカル インコーポレイテッド 遺伝子治療に適するプラスミド
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
CA2225460A1 (en) 1995-06-23 1997-01-09 Winston Campbell Patterson Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
EP0906444A1 (de) * 1996-04-19 1999-04-07 Gabriele Pecher Gentransfizierte humane dendritische zellen, ihre herstellung und ihre verwendung, bevorzugt als vakzine
ATE550042T1 (de) * 1997-11-20 2012-04-15 Vical Inc Behandlung von krebs mithilfe cytokin- exprimierender polynukleotide und zusammensetzungen dafür
US5948646A (en) * 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
AU7743100A (en) * 1999-09-30 2001-04-30 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
DE10139428A1 (de) 2001-08-17 2003-03-27 Nemod Immuntherapie Ag Herstellung und Verwendung von humanen CD124 und CD116 positiven Tumorzelllinien zur Herstellung von allogenen oder semi-allogenen Immuntherapeutika
ES2524442T3 (es) 2002-07-22 2014-12-09 Glycotope Gmbh Procedimiento para la producción de una mucina (MUC1) inmunoestimulante
DK1530628T3 (da) * 2002-08-16 2011-01-10 Glycotope Gmbh Fremgangsmåde til fremstilling af temperaturinducerede tumorcellelysater til anvendelse som immunogene forbindelser
SI1654353T1 (sl) 2003-08-18 2013-09-30 Glycotope Gmbh Tumorski celični liniji NM-F9 (DSM ACC2606) in NM-D4 (DSM ACC2605), njihove uporabe

Also Published As

Publication number Publication date
PT1654353E (pt) 2013-08-23
ES2425475T3 (es) 2013-10-15
CY1114643T1 (el) 2016-10-05
WO2005017130A3 (en) 2005-06-23
SI1654353T1 (sl) 2013-09-30
WO2005017130A2 (en) 2005-02-24
US8017388B2 (en) 2011-09-13
DK1654353T3 (da) 2013-08-26
US20060292129A1 (en) 2006-12-28
EP1654353B1 (en) 2013-05-22
EP1654353A2 (en) 2006-05-10
US8283161B2 (en) 2012-10-09
US20110319590A1 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
AP2280A (en) Compositions and methods for increasing telomeraseactivity.
AU2003262747A8 (en) Compounds, compositions, and methods
EP1503993A4 (en) COMPOUNDS, METHODS AND COMPOSITIONS
AU2003236527A8 (en) Compounds, compositions, and methods
AU2003265242A8 (en) Compounds, compositions, and methods
AU2003270015A8 (en) Compounds, compositions, and methods
GB0318099D0 (en) Mixing devices,systems and methods
MXPA03009132A (es) Alquilhidroxamatos triciclicos, su preparacion y su uso como inhibidores de la proliferacion de celulas.
AU2003299612A8 (en) Compounds, compositions and methods
SI1654353T1 (sl) Tumorski celični liniji NM-F9 (DSM ACC2606) in NM-D4 (DSM ACC2605), njihove uporabe
IL164581A0 (en) Compounds, compositions and methods
AU2003202130A8 (en) Document transformation
AU2003277079A8 (en) Compounds, compositions, and methods
AU2003290507A8 (en) Compounds, compositions and methods
GB0207205D0 (en) Polyurethane dispersion, manufacture and uses
GB2389858B (en) Firelighters
IL167936A0 (en) Compounds, compositions,and methods
AU2003300031A8 (en) Compounds, compositions, and methods
AU2003267169A8 (en) Compounds, compositions and methods
AP2006003512A0 (en) Woos treating formulation.
GB0305089D0 (en) Composition, use and process
IL177759A0 (en) Cospeptin, cosmedin and their uses
GB0229445D0 (en) Process,composition and use
GB0212528D0 (en) Dispersion
GB2385450A9 (en) Reviewing documents